摘要

Authors' objectives: This health technology assessment evaluates the effectiveness, safety, and cost-effectiveness of two enhanced visualization methods—hexaminolevulinate hydrochloride (HAL) and narrow band imaging (NBI)—used as adjuncts to white light during the first transurethral resection of bladder tumour (TURBT) in people with non-muscle-invasive bladder cancer (NMIBC). It also evaluates the budget impact of publicly funding these technologies.